Information Provided By: 
Fly News Breaks for July 25, 2017
PCRX
Jul 25, 2017 | 13:24 EDT
H.C. Wainwright analyst Corey Davis says that despite missing the primary efficacy endpoint in the femoral nerve block study, Pacira Pharmaceuticals now has what it needs to refile for Exparel label expansion with the FDA. Femoral nerve blocks are a "quickly fading market anyway," Davis tells investors in a research note. The analyst calls the brachial plexus study an "overwhelming success" and keeps a Buy rating on Pacira shares with a $59 price target.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
